Ligand to Report First Quarter Results on May 8th
SAN DIEGO -- April 22, 2013
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to
report first quarter 2013 financial results on Wednesday, May 8, 2013.
Ligand’s President and CEO, John Higgins, Executive Vice President and COO,
Matt Foehr and Vice President of Finance and CFO, John Sharp will host the
First Quarter Earnings Call
Ligand Pharmaceuticals conference call to discuss
What: financial results and provide general business
When: Wednesday, May 8, 2013
Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time)
Webcast: Conference call and replay accessible at
Conference Call: (877) 407-4019, passcode: Ligand
(201) 689-8337 outside the U.S.
Replay: (877) 660-6853, passcode: 396983
(201) 612-7415 outside the U.S.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company that develops and acquires assets it
believes will generate royalty revenues and, under its lean corporate cost
structure, produce sustainable profitability. Ligand has a diverse asset
portfolio addressing the unmet medical needs of patients for a broad spectrum
of diseases including thrombocytopenia, multiple myeloma, diabetes, hepatitis,
muscle wasting, dyslipidemia, anemia and osteoporosis. Ligand’s Captisol
platform technology is a patent-protected, chemically modified cyclodextrin
with a structure designed to optimize the solubility and stability of drugs.
Ligand has established multiple alliances with the world's leading
pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals,
Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck
Inc., Eli Lilly & Co., Spectrum Pharmaceuticals and The Medicines Company.
Please visit www.captisol.com for more information on Captisol or
www.ligand.com for more information on Ligand.
Follow Ligand on Twitter @Ligand_LGND.
Ligand Pharmaceuticals Incorporated
John Higgins, President and CEO
Jennifer Capuzelo, Investor Relations
Press spacebar to pause and continue. Press esc to stop.